CURRENT OASIS 7 [11]
|
CV death, MI, or stroke (MACE); CV death, MI, stroke, total mortality, TIMI major bleeding, minor bleeding, fatal bleeding, intracranial bleeding
|
30 days
|
DDC versus SDAPT
|
ACCEL AMI [12]
|
Minor bleeding
|
30 days
|
DDC versus SDAPT
|
OPTIMUS2007 [13]
|
Bleeding complications
|
30 days
|
DDC versus SDAPT
|
CREATIVE [14]
|
MACE, all-cause death, cardiac death, MI, TVR, stroke, ST, major bleeding
|
18 months
|
DDC versus SDAPT
|
Chen2017 [15]
|
MACE, in-stent thrombosis, TVR, MI, cardiac death, bleeding events, mild bleeding, severe bleeding
|
12 months
|
DDC versus SDAPT
|
Khatri2013 [16]
|
Composite efficacy outcomes, any bleeding event
|
23 months
|
DDC versus prasugrel
|
OPTIMUS3 [17]
|
Major and minor TIMI defined bleeding, adverse drug events
|
7 days
|
DDC versus prasugrel
|
PRINCIPLE TIMI 44 [18]
|
TIMI major and minor bleeding, minor bleeding, hemorrhagic adverse events, MI
|
2 weeks
|
DDC versus prasugrel
|
Tailor2014 [19]
|
MACE, MI, ST, CV death, stroke
|
1 month and 571 days
|
DDC versus prasugrel
|
Chen2017 [15]
|
MACE, in-stent thrombosis, TVR, MI, cardiac death, bleeding events, mild bleeding, severe bleeding
|
12 months
|
DDC versus ticagrelor
|
Wu2017 [20]
|
MACE, minimal bleeding, minor bleeding
|
30 days
|
DDC versus ticagrelor
|
ACCEL AMI [12]
|
Minor bleeding
|
30 days
|
DDC versus TAPT
|
ACCEL DM [21]
|
Bleeding event
|
30 days
|
DDC versus TAPT
|
CREATIVE [14]
|
MACE, all-cause death, cardiac death, MI, TVR, stroke, ST, major bleeding
|
18 months
|
DDC versus TAPT
|
Ha2013 [22]
|
MACE
|
1 month
|
DDC versus TAPT
|
HOST ASSURE [23]
|
MACE, cardiac death, MI, stroke, ST, all-cause death, TLR, TVR, PLATO minor bleeding
|
30 days
|
DDC versus TAPT
|
Jeong2009 [24]
|
MACE, major and minor bleeding
|
30 days
|
DDC versus TAPT
|